Literature DB >> 4790933

Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci.

C Watanakunakorn, C Bakie.   

Abstract

The in vitro activity of vancomycin and combinations of vancomycin-gentamicin and vancomycin-streptomycin against enterococci was investigated. The minimal inhibitory concentration of vancomycin for 99 of 100 enterococcal strains isolated clinically was 3.12 mug or less/ml. When cultures of eight strains were incubated with vancomycin, regardless of the inoculum size (10(6), 10(5), or 10(4)) and concentration of vancomycin (10 or 20 mug/ml), there was no significant reduction in the number of viable enterococci at 6, 24, and 48 h. Gentamicin and streptomycin in concentrations attainable clinically were not effective against enterococci. Vancomycin combined with gentamicin or streptomycin was tested against 41 enterococcal strains. With the combination of vancomycin at 10 mug/ml and gentamicin at 4 mug/ml or vancomycin at 5 mug/ml and gentamicin at 4 mug/ml, synergism was demonstrated against all 41 strains at 6 h. The combination of vancomycin at 10 mug/ml and streptomycin at 10 mug/ml was only synergistic against 25 of 41 strains at 6 h, and only 22 of 41 strains were affected synergistically at 6 h by vancomycin at 5 mug/ml with streptomycin at 10 mug/ml. With few exceptions, the enhanced killing was more pronounced at 24 and 48 h. The combination of vancomycin and gentamicin or vancomycin and streptomycin (where in vitro studies demonstrate synergism) may be a useful alternate therapy in enterococcal endocarditis.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4790933      PMCID: PMC444516          DOI: 10.1128/AAC.4.2.120

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Treatment of bacterial endocarditis in patients with penicillin hypersensitivity.

Authors:  G R Green; G A Peters; J E Gerach
Journal:  Ann Intern Med       Date:  1967-08       Impact factor: 25.391

Review 2.  The use of combinations of antimicrobial drugs.

Authors:  E Jawetz
Journal:  Annu Rev Pharmacol       Date:  1968       Impact factor: 13.820

3.  Treatment of bacterial endocarditis with cephalothin.

Authors:  J J Rahal; B R Meyers; L Weinstein
Journal:  N Engl J Med       Date:  1968-12-12       Impact factor: 91.245

4.  Vancomycin therapy for enterococcal and Streptococcus viridans endocarditis. Successful treatment of six patients.

Authors:  C K Friedberg; K M Rosen; P A Bienstock
Journal:  Arch Intern Med       Date:  1968-08

5.  Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center.

Authors:  G L Mandell; D Kaye; M E Levison; E W Hook
Journal:  Arch Intern Med       Date:  1970-02

Review 6.  Infective endocarditis in the antibiotic era.

Authors:  P I Lerner; L Weinstein
Journal:  N Engl J Med       Date:  1966-01-27       Impact factor: 91.245

7.  Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences.

Authors:  P Toala; A McDonald; C Wilcox; M Finland
Journal:  Am J Med Sci       Date:  1969-12       Impact factor: 2.378

8.  Antibiotic synergism: enhanced susceptibility of enterococci to combinations of streptomycin and penicillins or cephalosporins.

Authors:  F R Fekety; P Weiss
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

9.  Penicillin-streptomycin treatment of enterococcal endocarditis. A re-evaluation.

Authors:  E Jawetz; M Sonne
Journal:  N Engl J Med       Date:  1966-03-31       Impact factor: 91.245

10.  In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin and the combination of carbenicillin and gentamicin.

Authors:  J P Phair; C Watanakunakorn; T Bannister
Journal:  Appl Microbiol       Date:  1969-09
View more
  27 in total

1.  Efficacy of combined furazolidone and neomycin in the control of contamination in Leptospira cultures.

Authors:  D M Myers
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

2.  Synergism of oxacillin and gentamicin against enterococci.

Authors:  R L Marier; N Joyce; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

Review 3.  Antimicrobial resistance among enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Infectious disease emergencies. Part II: patients presenting with cardiac decompensation or circulatory insufficiency (shock).

Authors: 
Journal:  West J Med       Date:  1976-08

5.  Vancomycin-aminoglycoside combinations in therapy of endocarditis caused by Enterococcus species and Streptococcus bovis.

Authors:  J M Besnier; C Leport; A Buré; J L Vildé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

6.  Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci.

Authors:  J E Patterson; M J Zervos
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

7.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Gentamicin-resistant enterococci and endocarditis.

Authors:  R Holliman; E Smyth
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

9.  Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides.

Authors:  C Watanakunakorm; C Glotzbecker
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

10.  Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.

Authors:  S R Lavoie; E S Wong; P E Coudron; D S Williams; S M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.